John Strickler, MD

Articles

Unmet Needs and Future Perspectives in Colorectal Cancer

May 9th 2024

The panel concludes with perspectives on the future of treatment for patients with colorectal cancer, including unmet needs in the disease space.

Multidisciplinary Care for Patients with CRC

May 2nd 2024

Clinical insights on the roles of various members within a multidisciplinary team involved in the care of patients with colorectal cancer.

Toxicity Considerations and Treatment Decisions in CRC

May 2nd 2024

Experts on colorectal cancer discuss the treatment decision-making process, highlighting the safety profiles of fruquintinib and regorafenib.

Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma

April 18th 2024

Michael Leung, PharmD, presents the case of a 57-year-old man with cecal colon adenocarcinoma and provides his initial thoughts, particularly on adverse event management.

Treatment Considerations With Regorafenib in Colorectal Cancer

April 18th 2024

Focusing on the treatment of patients receiving regorafenib, the panel details the management of common adverse events, prophylaxis strategies, and the roles of members within a multidisciplinary team.

CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib

March 25th 2024

Strickler, Leung, Dasari, and O'Neill discuss adverse effect monitoring and management with standard agents for patients with colorectal cancer.

Dr. Strickler on the FDA Approval of Tucatinib Plus Trastuzumab in mCRC

January 19th 2023

John H. Strickler, MD, discusses the significance of the FDA approval of tucatinib plus trastuzumab in metastatic colorectal cancer.

Dr. Strickler on the Benefit of Combining Tucatinib With Trastuzumab in HER2+ CRC

October 14th 2022

John H. Strickler, MD, discusses the benefit of combining tucatinib with trastuzumab in HER2-positive metastatic colorectal cancer.

Dr. Strickler on the Importance of Targeted Therapies in HER2+ mCRC

October 5th 2022

John H. Strickler, MD, discusses the importance of investigating targeted therapies in HER2-positive metastatic colorectal cancer.

Dr. Strickler on the Exploration of Frontline Tucatinib/Trastuzumab in HER2+ CRC

August 29th 2022

John H. Strickler, MD, discusses the investigation of frontline tucatinib plus trastuzumab in HER2-positive colorectal cancer.

Dr. Strickler on the Rationale of Examining Tucatinib with Trastuzumab in HER2+ CRC

July 25th 2022

John H. Strickler, MD, discusses the rationale of tucatinib plus trastuzumab in HER2-positive colorectal cancer.

Dr. Strickler on Dosing Regorafenib in CRC

January 25th 2021

John H. Strickler, MD, discusses dosing strategies with regorafenib in colorectal cancer.

Dr. Strickler on the Rationale for the MOUNTAINEER-02 Trial in HER2+ Gastric/GEJ Cancer

January 15th 2021

John H. Strickler, MD, discusses the rationale for the phase 2/3 MOUNTAINEER-02 trial in HER2-positive gastric/gastroesophageal junction cancer.

Dr. Strickler on Genomic Variants Detected by Liquid Biopsies in GI Cancers

April 4th 2019

John Strickler, MD, assistant professor of medicine, Duke Cancer Institute, discusses genomic variants that can be detected by liquid biopsies in patients with gastrointestinal cancers.

Dr. Strickler on Therapies for Rare Variants of Relapsed/Refractory CRC

March 13th 2019

John Strickler, MD, assistant professor of medicine at Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses therapies for rare variants of relapsed/refractory colorectal cancer.

Dr. Strickler on the Value of Liquid Biopsies in CRC

January 5th 2019

John Strickler, MD, assistant professor of medicine, Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses the value of liquid biopsies in the treatment of patients with colorectal cancer (CRC).

Dr. Strickler on Applications for Liquid Biopsies in GI Cancer

December 21st 2018

John Strickler, MD, assistant professor of medicine, Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses applications for liquid biopsies in gastrointestinal cancer.

Dr. Strickler on the Importance of Molecular Markers in mCRC

December 6th 2018

John Strickler, MD, assistant professor of medicine, Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses improvements in the treatment of metastatic colorectal cancer.